Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;37(3):e3135.
doi: 10.1002/btpr.3135. Epub 2021 Feb 24.

Application of machine learning methods to pathogen safety evaluation in biological manufacturing processes

Affiliations

Application of machine learning methods to pathogen safety evaluation in biological manufacturing processes

Shyam Panjwani et al. Biotechnol Prog. 2021 May.

Abstract

The production of recombinant therapeutic proteins from animal or human cell lines entails the risk of endogenous viral contamination from cell substrates and adventitious agents from raw materials and environment. One of the approaches to control such potential viral contamination is to ensure the manufacturing process can adequately clear the potential viral contaminants. Viral clearance for production of human monoclonal antibodies is achieved by dedicated unit operations, such as low pH inactivation, viral filtration, and chromatographic separation. The process development of each viral clearance step for a new antibody production requires significant effort and resources invested in wet laboratory experiments for process characterization studies. Machine learning methods have the potential to help streamline the development and optimization of viral clearance unit operations for new therapeutic antibodies. The current work focuses on evaluating the usefulness of machine learning methods for process understanding and predictive modeling for viral clearance via a case study on low pH viral inactivation.

Keywords: biological manufacturing process; low pH viral inactivation; machine learning; monoclonal antibody; pathogen safety.

PubMed Disclaimer

Conflict of interest statement

A provisional patent application has already been filed to protect the intellectual property.

Figures

FIGURE 1
FIGURE 1
Schematic of purification process
FIGURE 2
FIGURE 2
For perfect class separation, there should not be any point in the band of width 2M. The red colored data points in the blue region and the blue colored data points in the red region are considered incorrectly classified. In case, a perfect separation is not possible, margin M is maximized by constraining the total distance of incorrectly classified data points from their respective margins
FIGURE 3
FIGURE 3
Decision tree for classification
FIGURE 4
FIGURE 4
Score plot provides an overview of performed experiments in a reduced dimensional space. Each data point in the score plot represents a single experiment. Score plot also helps in identifying groupings as shown by highlighted regions (Group‐1 and Group‐2)
FIGURE 5
FIGURE 5
Contribution plot enables the identification of process parameters responsible for the grouping of experimental runs
FIGURE 6
FIGURE 6
Loadings represent the relationship between the score vectors in a reduced dimensional space and process parameters
FIGURE 7
FIGURE 7
Confusion matrix for: (a) OPLS‐DA, (b) LR, (c) SVM, (d) DT, and (e) RF machine learning algorithms
FIGURE 8
FIGURE 8
Predictive loadings for OPLS‐DA classification model
FIGURE 9
FIGURE 9
A decision tree from the Random Forest classification model

References

    1. Schwantes A, Specht R, Chen Q. Proceedings of the 2017 viral clearance symposium, session 4: submission strategies. PDA J Pharm Sci Technol. 2018;72(5):498‐510. - PubMed
    1. Galbraith D. ICH Q5A. ICH Quality Guidelines 2017. 311‐335. https://onlinelibrary.wiley.com/doi/abs/10.1002/9781118971147.ch10 - DOI
    1. ASTM E2888‐12, Standard Practice for Process for Inactivation of Rodent Retrovirus by pH. West Conshohocken, PA2012.
    1. PAT — a framework for innovative pharmaceutical development, manufacturing, and quality assurance In: FDA, ed2004.
    1. Q8(R2) pharmaceutical development. In: FDA, ed2009.

Substances

LinkOut - more resources